Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6751 to 6765 of 7681 results

  1. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued [GID-TA10539]

    Technology appraisal guidance
    Discontinued

  2. Tisagenlecleucel for treating relapsed or refractory aggressive diffuse large B-cell lymphoma after 1 systemic therapy [ID3974]

    Discontinued [GID-TA10859]

    Technology appraisal guidance
    Discontinued

  3. Skin abscess: antimicrobial prescribing

    Discontinued [GID-NG10163]

    Antimicrobial prescribing guideline
    Discontinued

  4. Blepharitis: antimicrobial prescribing

    Discontinued [GID-NG10168]

    Antimicrobial prescribing guideline
    Discontinued

  5. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued [GID-TAG415]

    Technology appraisal guidance
    Discontinued

  6. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  7. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued [GID-TA11260]

    Technology appraisal guidance
    Discontinued

  8. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  9. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued [GID-TA11262]

    Technology appraisal guidance
    Discontinued

  10. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued [GID-TA10259]

    Technology appraisal guidance
    Discontinued

  11. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued [GID-TAG408]

    Technology appraisal guidance
    Discontinued

  12. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued [GID-TAG385]

    Technology appraisal guidance
    Discontinued

  13. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development [GID-TA10575] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    In development [GID-TA10961] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    In development [GID-TA10965] Expected publication date: TBC

    Technology appraisal guidance
    In development